Abu Dhabi Investment Authority to invest $200 million in India's medtech firm Meril

A wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) has entered into definitive agreements to invest $200 million for a ~3% stake in Micro Life Sciences Private Limited, one of India’s leading medical devices companies. 

The investment values Meril at an enterprise value of $6.6 billion. The transaction is subject to regulatory approval by the Competition Commission of India (CCI). Post this investment, Meril will be backed by two globally recognized investors, ADIA and Warburg Pincus. 

Founded by the Bilakhia Group, Meril focuses on clinically advanced solutions across multiple specialties, including cardiovascular, structural heart, orthopaedics, endo-surgery, in-vitro diagnostics and surgical robotics.

Headquartered in Vapi, India, Meril operates state-of-the-art, vertically integrated, and globally certified manufacturing and RCD facilities, across a 100 acre sustainable MedTech campus. The company employs more than 13,000 people, has 35+ global subsidiaries, and serves healthcare systems in 150+ countries.

Meril also has an in-house global RCD ecosystem and a portfolio of 200+ technology platforms. Through its 12+ global training academies, the company empowers over 10,000 healthcare professionals annually. 

Sanjeev Bhatt, Senior Vice President – Strategy, Meril said: “This investment by ADIA reinforces confidence in Meril’s long term vision and global ambitions. This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our RCD and clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions.” 

Established in 1976, the Abu Dhabi Investment Authority is a globally-diversified investment institution that prudently invests funds on behalf of the Government of Abu Dhabi through a strategy focused on long-term value creation.